Loading quotes...

Forecast

The analysts' average price target is €68.04 (+118.50%). The median is €68.04 (+118.50%).

Buy	6
Hold	0
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Maze Therapeutics: pipeline with MZE829 and MZE782 faces pivotal clinical data

Maze Therapeutics reported at the H.C. Wainwright conference progress on the APOL1 inhibitor MZE829 (Phase II HORIZON) and the PKU candidate MZE782. The company expects final HORIZON data by end‑2024/early‑2025 and plans to launch a registration‑enabling MZE829 program in H1 2025; a Phase II start for MZE782 in CKD is also planned for H1 2025, with top‑line PKU data expected in 2027. Early data show an average UACR reduction of 36% (50% responder rate) for MZE829 and a 42‑fold increase in urinary Phe excretion with MZE782; further development steps will depend largely on upcoming data, biomarker analyses and PARSOL‑Shield recommendations. » More on de.investing.com
Maze Therapeutics shows encouraging early data for MZE829 and MZE782, pivotal tests still pending

Maze Therapeutics presented early clinical signals at the Citigroup Biopharma Summit: the lead APOL1 program MZE829 showed a mean UACR reduction of 36% in 12 evaluable patients, with particularly strong effects in the FSGS subgroup. The PKU program MZE782 recorded a 42-fold increase in urinary phenylalanine excretion in Phase I and is already in Phase II. Management emphasized that key approval decisions, study-design discussions with the FDA and final HORIZON data are still outstanding; financial figures were not disclosed. » More on de.investing.com
Maze Therapeutics appoints Dr. Paula Johnson and Dr. Sophie Kornowski to the board

Maze Therapeutics has appointed Dr. med. Paula Johnson and Dr. pharm. Sophie Kornowski to its board of directors. Johnson brings more than 30 years of experience in clinical cardiology and research as well as leadership roles in academia and oversight bodies; Kornowski has over 35 years of executive experience in the biopharma industry, most recently as CEO of Boston Pharmaceuticals. The clinical biopharma company develops small‑molecule precision medicines for kidney and metabolic diseases and expects additional data on MZE829 in late 2026/early 2027 as well as initial data on MZE782 in 2027. » More on de.investing.com

Financials

In the last quarter, Maze Therapeutics had revenue of €0 and net profit of -€42.35m

(EUR)	September 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-42.35m	65.18%
EBITDA	-41.15m	63.60%

Fundamentals

Metric	Value
Market capitalization	€1.7bn
Number of shares	54.68m
52-week high/low	€48.67 - €19.91
Dividends	No
Beta	2.03
P/E ratio	-11.96
PEG ratio	0.40
P/B ratio	4.88
P/S ratio	93.86

Company profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.